Novocure earns CE mark for Optune Pax pancreatic cancer treatment device
June 30, 2026
Novocure (Nasdaq:NVCR) announced today that its Optune Pax device for treating pancreatic cancer received CE mark approval.
Novocure (Nasdaq:NVCR) announced today that its Optune Pax device for treating pancreatic cancer received CE mark approval.
StarMed announced today that it received FDA 510(k) clearance for its platform that delivers radiofrequency (RF) ablation of thyroid nodules.
One current viral health trend on TikTok claims that a combination of two over-the-counter drugs can help manage symptoms during those few days each month. Despite the lack of clinical trials to back up this seemingly odd blend of accessible medications, there is some biological reasoning behind this one.
Engineers have developed a new way to monitor how tiny lab-grown human heart tissues beat—by effectively “listening” to the ripples they create.
A biodegradable pressure sensor could help people with knee injuries exercise and heal faster, University of Connecticut researchers report in Science Advances. The
A new study presents an artificial intelligence system that scans images of the retina to detect signs of diabetes, high blood pressure, high cholesterol, gout, osteoporosis and thyroid disease in seconds.
New research shows that the only vaccine being tested to prevent and treat schistosomiasis can do both, and the researcher who made it possible is Afzal Siddiqui, Ph.D., from the Texas Tech University Health Sciences Center (TTUHSC).
MINNEAPOLIS, June 29, 2026 /PRNewswire/ — Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company’s pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
IntelliGenome, Inc., a molecular diagnostics company advancing next-generation tuberculosis detection technologies, today announced that Colombia’s National Institute for Food and Drug Surveillance (INVIMA) has granted sanitary registration for the CRISPR-TB Blood Test Kit.
Edwards Lifesciences (NYSE:EW) has earned FDA 510(k) clearance for Ecliptis, its left atrial appendage (LAA) exclusion system.